NASDAQ:LQDA - Liquidia Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.95 -0.09 (-0.90 %) (As of 05/22/2019 12:36 PM ET)Previous Close$10.04Today's Range$9.95 - $10.3752-Week Range$8.01 - $38.46Volume34,083 shsAverage Volume99,533 shsMarket Capitalization$185.50 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreements with GlaxoSmithKline plc and the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina. Receive LQDA News and Ratings via Email Sign-up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LQDA Previous Symbol CUSIPN/A CIKN/A Webhttp://www.liquidia.com/ Phone919-328-4400Debt Debt-to-Equity Ratio0.46 Current Ratio5.57 Quick Ratio5.57Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.71 million Price / Sales68.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book4.98Profitability EPS (Most Recent Fiscal Year)($7.51) Net Income$-53,140,000.00 Net Margins-1,964.76% Return on Equity-222.47% Return on Assets-78.32%Miscellaneous EmployeesN/A Outstanding Shares18,643,000Market Cap$185.50 million Next Earnings Date8/1/2019 (Estimated) OptionableNot Optionable Liquidia Technologies (NASDAQ:LQDA) Frequently Asked Questions What is Liquidia Technologies' stock symbol? Liquidia Technologies trades on the NASDAQ under the ticker symbol "LQDA." How were Liquidia Technologies' earnings last quarter? Liquidia Technologies Inc (NASDAQ:LQDA) announced its earnings results on Thursday, May, 2nd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.27. Liquidia Technologies had a negative net margin of 1,964.76% and a negative return on equity of 222.47%. View Liquidia Technologies' Earnings History. When is Liquidia Technologies' next earnings date? Liquidia Technologies is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Liquidia Technologies. What price target have analysts set for LQDA? 4 analysts have issued 12-month price objectives for Liquidia Technologies' stock. Their forecasts range from $27.00 to $49.00. On average, they anticipate Liquidia Technologies' stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 262.4% from the stock's current price. View Analyst Price Targets for Liquidia Technologies. What is the consensus analysts' recommendation for Liquidia Technologies? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Liquidia Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Liquidia Technologies. What are Wall Street analysts saying about Liquidia Technologies stock? Here are some recent quotes from research analysts about Liquidia Technologies stock: 1. According to Zacks Investment Research, "Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. " (5/8/2019) 2. Wedbush analysts commented, "BioTime reported updated Phase 1/2a interim data for OpRegen, retinal pigment epithelium (RPE) cell transplant therapy in dry age-related macular degeneration (AMD) with geographic atrophy (GA) at the Association for Research in Vision and Ophthalmology (ARVO)." (5/2/2019) Has Liquidia Technologies been receiving favorable news coverage? News articles about LQDA stock have trended neutral recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Liquidia Technologies earned a news impact score of 0.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. Who are some of Liquidia Technologies' key competitors? Some companies that are related to Liquidia Technologies include AngioDynamics (ANGO), Orthopediatrics (KIDS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR), SurModics (SRDX), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), SI-Bone (SIBN), GenMark Diagnostics (GNMK), MiMedx Group (MDXG), Accuray (ARAY), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), Westaim (WEDXF) and Vapotherm (VAPO). What other stocks do shareholders of Liquidia Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia Technologies investors own include Allena Pharmaceuticals (ALNA), Miragen Therapeutics (MGEN), Zynerba Pharmaceuticals (ZYNE), Cerecor (CERC), Clearside Biomedical (CLSD), Catalyst Pharmaceuticals (CPRX), Crispr Therapeutics (CRSP), Cytori Therapeutics (CYTX), Editas Medicine (EDIT) and Global Blood Therapeutics (GBT). Who are Liquidia Technologies' key executives? Liquidia Technologies' management team includes the folowing people: Mr. Neal F. Fowler, CEO & Director (Age 57)Mr. Robert A. Lippe, Chief Operations Officer (Age 54)Mr. William R. Kenan Jr., Co-FounderDr. Ginger Denison, Co-FounderMr. Timothy M. Albury, Interim Chief Financial Officer (Age 50) When did Liquidia Technologies IPO? (LQDA) raised $50 million in an initial public offering on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are Liquidia Technologies' major shareholders? Liquidia Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Canaan Partners VIII LLC (13.93%), ArrowMark Colorado Holdings LLC (7.10%), Samsara BioCapital LLC (3.43%), BlackRock Inc. (1.88%), Opaleye Management Inc. (1.21%) and Marshall Wace North America L.P. (0.89%). Company insiders that own Liquidia Technologies stock include Arthur S Kirsch, Benjamin Maynor, Kevin K Gordon, Plc Glaxosmithkline and Viii Lp Canaan. View Institutional Ownership Trends for Liquidia Technologies. Which institutional investors are selling Liquidia Technologies stock? LQDA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. Company insiders that have sold Liquidia Technologies company stock in the last year include Benjamin Maynor and Kevin K Gordon. View Insider Buying and Selling for Liquidia Technologies. Which institutional investors are buying Liquidia Technologies stock? LQDA stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Samsara BioCapital LLC, Opaleye Management Inc., Marshall Wace North America L.P., Jefferies Group LLC, BlackRock Inc., OZ Management LP and Canaan Partners VIII LLC. Company insiders that have bought Liquidia Technologies stock in the last two years include Arthur S Kirsch, Plc Glaxosmithkline and Viii Lp Canaan. View Insider Buying and Selling for Liquidia Technologies. How do I buy shares of Liquidia Technologies? Shares of LQDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Liquidia Technologies' stock price today? One share of LQDA stock can currently be purchased for approximately $10.21. How big of a company is Liquidia Technologies? Liquidia Technologies has a market capitalization of $190.35 million and generates $2.71 million in revenue each year. The company earns $-53,140,000.00 in net income (profit) each year or ($7.51) on an earnings per share basis. What is Liquidia Technologies' official website? The official website for Liquidia Technologies is http://www.liquidia.com/. How can I contact Liquidia Technologies? Liquidia Technologies' mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The company can be reached via phone at 919-328-4400 or via email at [email protected] MarketBeat Community Rating for Liquidia Technologies (NASDAQ LQDA)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 68 (Vote Outperform)Underperform Votes: 82 (Vote Underperform)Total Votes: 150MarketBeat's community ratings are surveys of what our community members think about Liquidia Technologies and other stocks. Vote "Outperform" if you believe LQDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LQDA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Book Value Per Share in Stock Trading Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.